BioTelemetry (BEAT) Downgraded by BidaskClub
BidaskClub downgraded shares of BioTelemetry (NASDAQ:BEAT) from a buy rating to a hold rating in a research note issued to investors on Saturday.
A number of other equities analysts also recently commented on BEAT. Dougherty & Co reiterated a buy rating and issued a $41.00 target price (up from $40.00) on shares of BioTelemetry in a report on Friday, February 23rd. Zacks Investment Research downgraded shares of BioTelemetry from a hold rating to a sell rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $43.00.
Shares of BioTelemetry (NASDAQ BEAT) traded up $1.05 during trading on Friday, reaching $32.55. 447,801 shares of the company’s stock were exchanged, compared to its average volume of 422,171. The company has a market capitalization of $1,060.00, a P/E ratio of -61.42, a PEG ratio of 1.60 and a beta of 0.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.77 and a quick ratio of 1.48. BioTelemetry has a fifty-two week low of $23.30 and a fifty-two week high of $39.20.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Nationwide Fund Advisors increased its holdings in shares of BioTelemetry by 2.1% during the second quarter. Nationwide Fund Advisors now owns 15,877 shares of the medical research company’s stock valued at $531,000 after acquiring an additional 328 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of BioTelemetry by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 21,949 shares of the medical research company’s stock valued at $734,000 after acquiring an additional 763 shares in the last quarter. Voya Investment Management LLC increased its holdings in shares of BioTelemetry by 9.4% during the second quarter. Voya Investment Management LLC now owns 13,644 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 1,177 shares in the last quarter. Comerica Bank increased its holdings in shares of BioTelemetry by 3.2% during the fourth quarter. Comerica Bank now owns 51,106 shares of the medical research company’s stock valued at $1,778,000 after acquiring an additional 1,591 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. increased its holdings in shares of BioTelemetry by 21.5% during the fourth quarter. Campbell Newman Asset Management Inc. now owns 10,134 shares of the medical research company’s stock valued at $303,000 after acquiring an additional 1,796 shares in the last quarter. Hedge funds and other institutional investors own 83.93% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “BioTelemetry (BEAT) Downgraded by BidaskClub” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.watchlistnews.com/biotelemetry-beat-downgraded-by-bidaskclub/1907054.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.